Exforge receives US regulatory approval as a new and highly effective treatment option for patients with high blood pressure.

(From Chemical Business NewsBase - Press Release)

Novartis announced the US regulatory approval of Exforge as a new treatment option for patients with high blood pressure. Exforge combines in one tablet the two most commonly prescribed hypertension medicines in their categories - Diovan (valsartan) and Norvasc (amlodipine besylate). The US Food and Drug Administration (FDA) issued this tentative approval because Exforge has met all the required standards for safety, efficacy and manufacturing quality. Exforge …